1327P A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc)
Antonia S, Goldberg S, Balmanoukian A, Narwal R, Robbins P, D'Angelo G, Blake-Haskins A, Karakunnel J, Rizvi N. 1327P A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc). Annals Of Oncology 2014, 25: iv466. DOI: 10.1093/annonc/mdu349.106.Peer-Reviewed Original ResearchStock/stock optionsDrug-related AEsClinical trialsAdvanced non-small cell lung cancerT-lymphocyte-associated protein 4Non-small cell lung cancerCurrent safety profileDose-expansion phaseSafety/tolerabilityAntitumor activityHuman IgG2 monoclonal antibodyDose-escalation phasePhase 1 studyImmune cell phenotypesCell lung cancerCell death 1Cell death ligandPD-L1 bindingGreater antitumor activityAnti-tumor activityT cell activationHuman IgG1 mAbBoehringer Ingelheim PharmaceuticalsCohort 1aECOG PS